OTP Take-Home Doses Under the Revised 42 CFR Part 8: The Documentation File Surveyors Sample First

When SAMHSA revised the federal opioid treatment program rules in 2024, most operators read the take-home section once, updated a policy, and moved on. The policy is rarely the problem. The problem shows up eighteen months later, when a surveyor pulls five charts of patients on extended take-homes and asks a simple question: where is the clinical reasoning for this schedule, and who signed it? This post walks through what the revised rule actually changed, what reviewers sample, and the take-home file an opioid treatment program (OTP) should be able to produce for any patient on the day it is asked.

This is operational guidance for owners, medical directors and compliance officers. It is not legal advice, and your State Opioid Treatment Authority may set rules stricter than the federal floor.

The Federal Take-Home Schedule in One Paragraph

Under the revised federal opioid treatment program regulations at 42 CFR Part 8, which SAMHSA finalized in 2024 with a compliance date of October 2, 2024, an OTP practitioner may allow a patient up to 7 days of methadone take-home doses during the first 14 days of treatment, up to 14 days from day 15 of treatment, and up to 28 days from day 31 of treatment. Those are maximums, not entitlements: each take-home decision rests on the practitioner’s clinical judgment, must weigh the factors the rule lists, and must be documented in the patient record. States may impose tighter limits, and where they do, the stricter rule controls.

Read that paragraph again with your chart audit tool open. The schedule is the easy part. The words that matter for a survey are “clinical judgment,” “factors,” and “documented.”

What Actually Changed in 2024

Before the revision, take-home eligibility was tied to a longer time-in-treatment ladder and a fixed list of criteria that programs tended to treat as a checklist. The 2024 rule, published by SAMHSA and codified in the current text of 42 CFR Part 8, compressed the timeline and moved the decision toward individualized clinical judgment. SAMHSA’s own opioid treatment program guidance frames this as patient-centered care rather than a reward system for compliance.

For operators, that shift cuts both ways. A program now has more latitude to extend take-homes earlier. It also has less cover. Under a checklist model, a chart that ticked every box was defensible on its face. Under a judgment model, the reviewer is looking for the judgment itself, written down, by someone authorized to make it.

What a Reviewer Samples First

Whether the visit is a state OTP inspection, an accreditation survey or a SAMHSA certification review, the pattern is similar. The reviewer typically starts from the dosing system, not from the policy binder. They pull a list of patients currently on take-homes, sort it by the number of take-home days, and pick from the top. Patients early in treatment with multi-day supplies are the first charts opened, because that is where the revised rule gives the most latitude and where the documentation is most often thin.

For each sampled chart, expect them to look for four things in sequence: the current take-home order, the clinical rationale behind it, the date it was last reassessed, and evidence that the patient was counseled on safe storage. They will then walk to the dispensing area and compare the order in the chart to what the dosing staff actually dispensed that week. A mismatch between the electronic order and the dispensing log is one of the fastest ways to turn a documentation finding into a patient safety finding.

Why Take-Home Charts Fail Review

When take-home documentation draws a finding, it almost always traces back to one of a small number of causes.

• Template drift: the policy was updated for the 2024 schedule, but the EHR order template, the dosing software rules or the nurse’s dispensing sheet still enforce the old ladder, so practice and policy disagree.
• Rationale by checkbox: the chart shows a completed eligibility form but no narrative tying the specific schedule to this patient’s stability, home situation and risk, which is exactly what a judgment-based rule asks for.
• Stale reassessment: the schedule was justified when it began, but there is no documented review after a positive toxicology result, a missed dosing day or a change in housing.
• Unsigned authority: the order was entered by staff who are not authorized under your state rules or program policy to approve take-home changes, or the approving practitioner’s signature is missing.
• Diversion plan disconnect: the program’s required diversion control plan describes callbacks and bottle checks, but no chart shows one ever happened.

The first cause is the one we see most often, and it is the least visible from inside the program. Clinical leadership updates the policy. Nobody tells the EHR administrator. For months the dosing system quietly caps patients at the old limits, or, worse, allows extended supplies with no rationale field required. Neither situation shows up until someone compares the policy, the template and the dispensing log side by side.

The Take-Home File: What Belongs in Every Chart

For any patient receiving unsupervised doses, you should be able to produce the following within minutes, without hunting through scanned attachments.

• The current order: number of take-home days, effective date and the authorizing practitioner’s signature.
• A written rationale: a short narrative addressing the factors the federal rule lists and any additional factors your state requires, specific to this patient, not copied forward.
• Reassessment history: dated reviews at the intervals your policy sets, plus event-driven reviews after anything that bears on stability.
• Safe storage counseling: documentation that the patient was educated on secure storage and on keeping medication away from children and others in the home, with the date.
• Diversion control activity: callback or bottle-return results where your diversion control plan calls for them.
• Toxicology linkage: recent results and the documented clinical response to any unexpected result.

Methadone take-homes also sit inside DEA controlled substance recordkeeping. Dispensing records must reconcile with the take-home orders in the chart. The DEA Diversion Control Division publishes the registrant requirements your dispensing records must meet; your take-home file and your DEA records should tell the same story for the same patient on the same day.

What to Do This Week

You do not need a full mock survey to find out whether your take-home documentation will hold. Run this three-way check before Friday.

1. Pull a report from your dosing system of every patient currently on take-homes, sorted by number of take-home days, highest first.
2. Take the top ten, plus every patient in their first 30 days of treatment who has more than one take-home day.
3. For each, put three things side by side: the take-home section of your current policy, the order in the EHR, and last week’s dispensing log entries.
4. Mark any chart where the rationale is a checkbox only, the last reassessment predates a positive toxicology result, or the authorizing signature is missing.
5. Open your EHR order template and confirm it reflects the 2024 schedule and your state’s limits, and that it will not save a take-home order without a rationale.

If more than two of the ten charts fail any element, treat it as a systemic issue, not a staff coaching issue. Fix the template first, then retrain, then re-audit the same sample in 30 days so you have evidence of correction on file before anyone asks.

Where State Rules Change the Answer

The federal schedule sets the outer limit of what Part 8 permits; it does not require your state to allow the same. Several states kept their own take-home rules, adopted the federal changes on a delay, or require State Opioid Treatment Authority approval for exceptions. Before you extend any patient beyond what your program offered under the old ladder, confirm your state’s current position in writing and file that confirmation with the policy. A surveyor who finds a schedule permitted federally but restricted by the state will cite the state rule.

Accreditation adds a third layer. Joint Commission and CARF surveyors evaluate whether your medication management and record practices match your own written policies. If your policy says reassessment happens monthly and the charts show quarterly, that gap is a finding regardless of what Part 8 allows. Our Joint Commission accreditation consulting and CARF accreditation consulting teams see this mismatch more often than any outright regulatory violation.

Getting Help With Take-Home Documentation

If your policy, EHR templates and dispensing records have not been reconciled since the 2024 rule took effect, a focused review is faster than a full mock survey. Circa Behavioral’s fractional compliance officer service can run the three-way chart check, fix the template gaps and build the re-audit evidence your surveyors will ask for. Call (888) 458-6619 to schedule a review.

Already have a survey on the calendar? Reach our team directly at (888) 458-6619 and we will help you prioritize the charts most likely to be sampled.